Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
AlphaCentric LifeSci Healthcare A LYFAX
- NAV / 1-Day Return 13.61 / +1.04 %
- Total Assets 81.9 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.660%
- Distribution Fee Level High
- Share Class Type Front Load
- Category Health
- Investment Style Small Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 134%
USD | NAV as of Oct 04, 2024 | 1-Day Return as of Oct 04, 2024, 10:29 PM GMT+0
Morningstar’s Analysis LYFAX
Will LYFAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 38.6
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
United Therapeutics Corp | 5.58 | 4.6 Mil | Healthcare |
First American Treasury Obligs X | 5.13 | 4.2 Mil | Cash and Equivalents |
BioCryst Pharmaceuticals Inc | 5.04 | 4.2 Mil | Healthcare |
Pfizer Inc | 4.73 | 3.9 Mil | Healthcare |
Harmony Biosciences Holdings Inc Ordinary Shares | 4.44 | 3.7 Mil | Healthcare |
Pacira BioSciences Inc | 4.06 | 3.4 Mil | Healthcare |
argenx SE ADR | 3.76 | 3.1 Mil | Healthcare |
Galapagos NV ADR | 3.25 | 2.7 Mil | Healthcare |
Mirum Pharmaceuticals Inc | 2.64 | 2.2 Mil | Healthcare |
BeiGene Ltd ADR | 2.58 | 2.1 Mil | Healthcare |